BREAKING: Lilly to buy ImClone for $6B

View as web page ,  View as PDF
	Monday, October 6, 2008 8:10 AM
	Lilly to buy ImClone for $6B Eli Lilly and Co. this morning announced that it has agreed to buy biotechnology company ImClone Systems Inc. for more than $6 billion, a deal that expands Lilly's pipeline of cancer treatments. Indianapolis-based Lilly said it will pay $70 per share for New York-based ImClone. "We really do create an oncology powerhouse," Lilly CEO John Lechleiter said this morning in an interview on CNBC. ImClone previously had rejected as too low two takeover offers from New York-based Bristol-Myers Squibb Co., its marketing partner for the cancer drug Erbitux. Bristol-Myers made bids of $60 and later of $62 per share. ImClone says Chairman Carl Icahn, who owns about 14 percent of ImClone stock, has agreed to vote in favor of the Lilly deal.
	IBJ Daily hosted and delivered by Unsubscribe | Update Profile | Manage Subscriptions We respect your right to privacy - click here to view our policy. Copyright © IBJ Media Corp. 2007. All Rights Reserved. Privacy Policy Reproduction or use without permission of editorial or graphic content in any manner is strictly prohibited. Reprint orders: To request reprint permission contact IBJ's managing editor. Phone: 317-634-6200 - E-mail: managingeditor@ibj.com This email was sent by: IBJ Corporation 41 East Washington Street, Suite 200 Indianapolis, IN, 46204-3592, United States of America